Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife—The PESA Observational Study

Raquel Toribio-Fernández,Catarina Tristão-Pereira,Juan Carlos Silla-Castro,Sergio Callejas,Belen Oliva,Irene Fernandez-Nueda,Ines Garcia-Lunar,Cristina Perez-Herreras,José María Ordovás,Pilar Martin,Fiona Blanco-Kelly,Carmen Ayuso,Enrique Lara-Pezzi,Antonio Fernandez-Ortiz,Ana Garcia-Alvarez,Ana Dopazo,Fatima Sanchez-Cabo,Borja Ibanez,Marta Cortes-Canteli,Valentin Fuster
DOI: https://doi.org/10.1161/circresaha.123.323921
IF: 23.213
2024-01-25
Circulation Research
Abstract:Circulation Research, Ahead of Print. Background:APOE is a known genetic contributor to cardiovascular disease, but the differential roleAPOEalleles play in subclinical atherosclerosis remains unclear.Methods:The PESA (Progression of Early Subclinical Atherosclerosis) is an observational cohort study that recruited 4184 middle-aged asymptomatic individuals to be screened for cardiovascular risk and multiterritorial subclinical atherosclerosis. Participants wereAPOE-genotyped, and omics data were additionally evaluated.Results:In the PESA study, the frequencies forAPOE-ε2, -ε3, and -ε4 alleles were 0.060, 0.844, and 0.096, respectively. This study included a subcohort of 3887 participants (45.8±4.3 years of age; 62% males). As expected,APOE-ε4 carriers were at the highest risk for cardiovascular disease and had significantly greater odds of having subclinical atherosclerosis compared with ε3/ε3 carriers, which was mainly explained by their higher levels of LDL (low-density lipoprotein)-cholesterol. In turn,APOE-ε2 carriers were at the lowest risk for cardiovascular disease and had significantly lower odds of having subclinical atherosclerosis in several vascular territories (carotids: 0.62 [95% CI, 0.47–0.81];P=0.00043; femorals: 0.60 [0.47–0.78];P=9.96×10−5; coronaries: 0.53 [0.39–0.74];P=0.00013; and increased PESA score: 0.58 [0.48–0.71];P=3.16×10−8). ThisAPOE-ε2 atheroprotective effect was mostly independent of the associated lower LDL (low-density lipoprotein)-cholesterol levels and other cardiovascular risk factors. The protection conferred by the ε2 allele was greater with age (50–54 years: 0.49 [95% CI, 0.32–0.73];P=0.00045), and normal (<150 mg/dL) levels of triglycerides (0.54 [0.44–0.66];P=4.70×10−9versus 0.90 [0.57–1.43];P=0.67 if ≥150 mg/dL). Omics analysis revealed an enrichment of several canonical pathways associated with anti-inflammatory mechanisms together with the modulation of erythrocyte homeostasis, coagulation, and complement activation in ε2 carriers that might play a relevant role in the ε2's atheroprotective effect.Conclusions:This work sheds light on the role of APOE in cardiovascular disease development with important therapeutic and prevention implications on cardiovascular health, especially in early midlife.REGISTRATION:URL:https://www.clinicaltrials.gov: NCT01410318.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
What problem does this paper attempt to address?